Community-acquired pneumonia: What is relevant and what is not?

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 3, 2007, Pages 177-185

  Talwar, Arunabh ^a   Lee, Hans ^a   Fein, Alan ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibiotics; Community acquired pneumonia; Immunization; Prevention

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; GATIFLOXACIN; GEMIFLOXACIN; IMIPENEM; INFLUENZA VACCINE; LEVOFLOXACIN; LINEZOLID; LIVE VACCINE; MACROLIDE; MEROPENEM; METICILLIN; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TELITHROMYCIN; UNINDEXED DRUG;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; EMPIRICISM; GRAM NEGATIVE BACTERIUM; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; INFECTION RISK; INFLUENZA VACCINATION; LABORATORY TEST; MEDICAL LITERATURE; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOME ASSESSMENT; PATHOGENESIS; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MORBIDITY; NORTH AMERICA; PNEUMONIA; PRACTICE GUIDELINES; PREVALENCE; RISK FACTORS; SMOKING CESSATION; VACCINATION;

EID: 34247172557     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3280f6cf02     Document Type: Review

References (78)

1. Medicare and medicaid statistical supplement, 1995. Health Care Financ Rev Stat Suppl 1995; 1-388.
2. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002; 347:2039-2045.
3. Rhew DC, Tu GS, Ofman J, et al. Early Switch and early discharge strategies in patients with community-acquired pneumonia. Arch Intern Med 2001; 161:722-727.
4. Speets AM, Hoes AW, van der Graaf Y, et al. Chest radiography and pneumonia in primary care: diagnostic yield and consequences for patient management. Eur Respir J 2006; 28:933-938.
5. Levin KP, Hanusa BH, Rotondi A, et al. Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. J Gen Intern Med 2001; 16:590-598.
6. Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123:174-180.
7. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433.
8. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118:1344-1354.
9. El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163 (3 Pt 1):645-651.
10. Van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60:672.
11. Francis JDM, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistnat staphylococcus aureus carrying the panton-valentine leukocidin genes. BMJ 2005; 40:100-107.
12. Leung WS, Chu CM, Tsang KY, et al. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129:102-109. A recent article on emerging pathogens for CAP
13. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-1297.
14. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139-148.
15. Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365:855-863.
16. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-1444.
17. Rice L. Antimicrobial resistance in gram-positive bacteria. Am J Med 2006; 119:11-19.
18. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.
19. Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 2003; 124:2148-2155.
20. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
21. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-382.
22. Bauer TT, Ewig S, Marre R, Muller EE. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260:93-101.
23. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27:151-157.
24. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384-392.
25. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138-1180.
26. Moine P, Vercken JB, Chevret S, et al. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994; 105:1487-1495.
27. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134-141.
28. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991-2001.
29. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148:1418-1426.
30. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158:1102-1108.
31. Cordero E, Pachon J, Rivero A, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med 2000; 162:2063-2068.
32. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-723.
33. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59:960-965.
34. Dean NC, Bateman KA, Donnelly SM, et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006; 130:794-799.
35. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-644.
36. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278:2080-2084.
37. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-382.
38. Shefet D, Robenshtok E, Paul M, et al. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005; 165:1992-2000.
39. Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128:172-183.
40. Garcia Vazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24:190-195.
41. Amsden GW. Anti-inflammatory effects of macrolides: an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55:10-21.
42. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842.
43. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-444.
44. El Moussaoui R, de Borgie CA, Van den broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double blind study. BMJ 2006; 332:1355.
45. Sabria M, Pedro-Botet ML, Gomez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128:1401-1405.
46. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452-1457.
47. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community acquired streptococcus pneumonia. Arch Intern Med 2001; 161:848-850.
48. Menendez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39:1783-1790.
49. Nathan R, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119:512.
50. Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000; 22:250-264.
51. Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125:1335-1342.
52. van der Meer V, Neven AK, van den Broek PJ, et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331:26.
53. Christ-Crain MSD, Stolz D, Bingisser R, et al. Procalcitonin: guidance of antibiotic therapy in community-acquired pneumonia. Am J Resp Crit Care Med 2006; 174:84-93.
54. Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005; 33:257-263.
55. Quasney MW, Waterer GW, Dahmer MK, et al. Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. Crit Care Med 2004; 32:1115-1119.
56. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study. Am J Resp Crit Care Med 2005; 171:242-248.
57. van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61:957-961.
58. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.
59. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33:952-961.
60. Maskell NA, Davies CW, Nunn AJ, et al. Fibrinolytic therapy provided no clinical benefit in elderly patients with infected parapneumonic effusions. Clin Infect Dis 2005; 40:1288-1297.
61. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755.
62. Cornu C, Yzebe D, Leophonte P, et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780-4790.
63. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; CD000422.
64. Fisman DN, Abrutyn E, Spaude KA, et al. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42:1093-1101.
65. Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23:363-368.
66. Vila-Corcoles A, Ochoa-Gondar O, Llor C, et al. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Respir J 2005; 26:1086-1091.
67. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051.
68. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-1463. This study puts forth the view that use of conjugate vaccines in children has decreased the level of resistance among adults
69. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2207-2217.
70. Spaude KA, Abrutyn E, Kirchner C, et al. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007; 167:53-59.
71. Smith NM, Breese JS, Shay DK, et al. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006; 55:1-42. This report provides the current guidelines for vaccination of adults for Influenza, by the CDC.
72. Harper S, Fukuda K, Uyeki TM, et al. CDC-Prevention and control of Influenza. Recommendations of the Advisory Committee On Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1-40.
73. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417-2422.
74. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681-689.
75. Talwar A, Jain M, Vijayan VK. Pharmacotherapy of tobacco dependence. Med Clin North Am 2004; 88:1517-1534.
76. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63.
77. Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence: Clinical practice guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; June 2000.
78. Tonnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29:390-417. A current article on smoking cessation amongst patients with known respiratory illnesses.